Advanced search
Publication Cover
Acta Oncologica Volume 50, 2011 - Issue 5
Journal homepage
1,346
Views
31
CrossRef citations to date
0
Altmetric
Research Article

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials

Silvia Hofer Department of Oncology, University Hospital Zurich, SwitzerlandCorrespondence[email protected]
,
Katarzyna Elandt Department of Internal Medicine I, University Hospital Vienna, Austria
,
Richard Greil Third Medical Department at the Private Medical University Hospital Salzburg, Austria
,
Andreas F. Hottinger Department of Oncology University Hospital Geneva, Switzerland
,
Urs Huber Swiss Tumor Institute, Onkozentrum Klinik im Park, Zurich, Switzerland
,
Dieter Lemke Department of Neurooncology, National Center for Tumour Disease and Neurology Clinic, University Hospital Heidelberg, Germany
,
Christine Marosi Department of Internal Medicine I, University Hospital Vienna, Austria
,
Adrian Ochsenbein Department of Oncology, University Hospital Bern, Switzerland
,
Josef Pichler Department of Internal Medicine and Neurooncology, Landesnervenklinik Linz, Austria
,
Ulrich Roelcke Department of Neurooncology and Medical Oncology, Kantonsspital Aarau, Switzerland
,
Patrik Weder Department of Oncology, Kantonsspital St. Gallen, Switzerland
,
Thilo Zander Department of Oncology, Kantonsspital Luzern, Switzerland
,
Wolfgang Wick Department of Neurooncology, National Center for Tumour Disease and Neurology Clinic, University Hospital Heidelberg, Germany
&
Michael Weller Department of Neurology, University Hospital Zurich, Switzerland
 show all
Pages 630-635 | Received 26 Jan 2011, Accepted 14 Mar 2011, Published online: 18 Apr 2011

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Casey Anthony, Nikol Mladkova-Suchy & David Cory Adamson. (2019) The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential. Expert Opinion on Investigational Drugs 28:9, pages 787-797.
Read now
Anders Toft, Thomas Urup, Ib Jarle Christensen, Signe Regner Michaelsen, Babloo Lukram, Kirsten Grunnet, Michael Kosteljanetz, Vibeke Andrée Larsen, Ulrik Lassen, Helle Broholm & Hans Skovgaard Poulsen. (2018) Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. Cancer Investigation 36:2, pages 165-174.
Read now
Emilie Le Rhun, Sophie Taillibert & Marc C Chamberlain. (2015) Anaplastic glioma: current treatment and management. Expert Review of Neurotherapeutics 15:6, pages 601-620.
Read now
Mustafa Khasraw, Malaka Ameratunga & Christian Grommes. (2014) Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials. Expert Opinion on Biological Therapy 14:5, pages 729-740.
Read now
Ane B. Iversen, Morten Busk & Michael R. Horsman. (2013) Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Acta Oncologica 52:7, pages 1320-1326.
Read now
Olivier L Chinot. (2012) Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date. Expert Review of Anticancer Therapy 12:11, pages 1413-1427.
Read now
Saadettin Kilickap, Ibrahim Oztoprak & Birsen Yucel. (2012) Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme. Acta Oncologica 51:4, pages 544-546.
Read now
Pol Specenier. (2012) Bevacizumab in glioblastoma multiforme. Expert Review of Anticancer Therapy 12:1, pages 9-18.
Read now

Articles from other publishers (23)

Rebecca Kassubek, Dorothée Lulé, Albert C. Ludolph, Jan Kassubek & Hans-Peter Müller. (2023) Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma. Frontiers in Neurology 14.
Crossref
Needa A. Virani, Olivia J. Kelada, Sijumon Kunjachan, Alexandre Detappe, Jihun Kwon, Jennifer Hayashi, Ana Vazquez-Pagan, Douglas E. Biancur, Thomas Ireland, Rajiv Kumar, Srinivas Sridhar, G. Mike Makrigiorgos & Ross I. Berbeco. (2020) Noninvasive imaging of tumor hypoxia after nanoparticle-mediated tumor vascular disruption. PLOS ONE 15:7, pages e0236245.
Crossref
Sara Hanaei, Víctor Andrés Arrieta & Adam M. Sonabend. 2020. Cancer Immunology. Cancer Immunology 379 425 .
Veronica Villani, Alessandra Fabi, Antonio Tanzilli, Francesco Pasqualetti, Giuseppe Lombardi, Antonello Vidiri, Alessandra Gonnelli, Alessandro Molinari, Martina Cantarella, Luisa Bellu, Irene Terrenato, Mariantonia Carosi, Marta Maschio, Stefano Maria Telera, Carmine Maria Carapella, Francesco Cognetti, Fabiola Paiar, Vittorina Zagonel & Andrea Pace. (2019) A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?. Future Oncology 15:15, pages 1717-1727.
Crossref
Jennifer Jeck, Rebecca Kassubek, Jan Coburger, Simone Edenhofer, Stefan S. Schönsteiner, Albert C. Ludolph, Bernd Schmitz, Jens Engelke, Regine Mayer-Steinacker, Jan Lewerenz & Lars Bullinger. (2018) Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature. Therapeutic Advances in Neurological Disorders 11, pages 175628561775359.
Crossref
Michele Reni, Elena Mazza, Silvia Zanon, Gemma Gatta & Charles J. Vecht. (2017) Central nervous system gliomas. Critical Reviews in Oncology/Hematology 113, pages 213-234.
Crossref
Oguz Ozel, Mehmet Kurt, Oguzhan Ozdemir, Jale Bayram, Huseyin Akdeniz & Dogan Koca. (2016) Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review. Journal of Oncological Sciences 2:2-3, pages 87-94.
Crossref
ZHIYUN YU, GANG ZHAO, ZHONGHUA ZHANG, YUNQIAN LI, YONG CHEN, NAN WANG, ZHONGYING ZHAO & GUIFANG XIE. (2016) Efficacy and safety of bevacizumab for the treatment of glioblastoma. Experimental and Therapeutic Medicine 11:2, pages 371-380.
Crossref
Josa M. Frischer, Christine Marosi, Adelheid Woehrer, Johannes A. Hainfellner, Karin Ute Dieckmann, Helmut Eiter, Wei-Te Wang, Ammar Mallouhi, Adolf Ertl, Engelbert Knosp, Martin Filipits, Klaus Kitz & Brigitte Gatterbauer. (2016) Gamma Knife Radiosurgery in Recurrent Glioblastoma. Stereotactic and Functional Neurosurgery 94:4, pages 265-272.
Crossref
Clara Chen, Arliene Ravelo, Elaine Yu, Rahul Dhanda & Ian Schnadig. (2015) Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices. Journal of Neuro-Oncology 122:3, pages 595-605.
Crossref
Adama Sacko, Miao-Miao Hou, Michael Temgoua, Ali Alkhafaji, Athina Marantidou, Catherine Belin, Emmanuel Mandonnet, Renata Ursu, Jennifer Doridam, Ir?ne Coman, Christine Levy-Piedbois & Antoine F. Carpentier. (2015) Evolution of the Karnosky Performance Status throughout life in glioblastoma patients. Journal of Neuro-Oncology 122:3, pages 567-573.
Crossref
Kien Pham, Defang Luo, Dietmar W. Siemann, Brian K. Law, Brent A. Reynolds, Parvinder Hothi, Gregory Foltz & Jeffrey K. Harrison. (2015) VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. Cancer Letters 360:1, pages 60-67.
Crossref
G. Simonetti, E. Trevisan, A. Silvani, P. Gaviani, A. Botturi, E. Lamperti, D. Beecher, L. Bertero, C. Bosa & A. Salmaggi. (2013) Safety of bevacizumab in patients with malignant gliomas: a systematic review. Neurological Sciences 35:1, pages 83-89.
Crossref
E. Tabouret, M. Barrie, A. Thiebaut, M. Matta, C. Boucard, D. Autran, A. Loundou & O. Chinot. (2013) Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen. Journal of Neuro-Oncology 114:2, pages 191-198.
Crossref
Yoshitaka Narita. (2013) Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors. Japanese Journal of Clinical Oncology 43:6, pages 587-595.
Crossref
Umut Demirci, Gulnihal Tufan, Bilge Aktas, Ozan Balakan, Ahmet Alacacioglu, Faysal Dane, Huseyin Engin, M. Ali Kaplan, Yusuf Gunaydin, Nuriye Y. Ozdemir, I. Tugba Unek, Halit Karaca, Tulay Akman, Ozlem U. Sonmez, Ugur Coskun, Hakan Harputluoglu, Alper Sevinc, Onder Tonyali, Suleyman Buyukberber & Mustafa Benekli. (2013) Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). Journal of Cancer Research and Clinical Oncology 139:5, pages 829-835.
Crossref
J. M. Lupo, E. Essock-Burns, A. M. Molinaro, S. Cha, S. M. Chang, N. Butowski & S. J. Nelson. (2013) Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro-Oncology 15:4, pages 480-489.
Crossref
Pierre Giglio, Megha Dhamne, Kenneth R. Hess, Mark R. Gilbert, Morris D. Groves, Victor A. Levin, Sanghee L. Kang, Sandra E. Ictech, Vivien Liu, Howard Colman, Charles A. Conrad, Monica Loghin, John de Groot, W. K. Alfred Yung & Vinay K. Puduvalli. (2011) Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118:14, pages 3599-3606.
Crossref
Daniel T. Nagasawa, Christina Fong, Andrew Yew, Marko Spasic, Heather M. Garcia, Carol A. Kruse & Isaac Yang. (2012) Passive Immunotherapeutic Strategies for the Treatment of Malignant Gliomas. Neurosurgery Clinics of North America 23:3, pages 481-495.
Crossref
Daniel T. Nagasawa, Frances Chow, Andrew Yew, Won Kim, Nicole Cremer & Isaac Yang. (2012) Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme. Neurosurgery Clinics of North America 23:2, pages 307-322.
Crossref
Annick Desjardins & John H. Sampson. (2012) Editorial. Journal of Neurosurgery 116:2, pages 336-340.
Crossref
Christoph Oehler, Karl Frei, Elisabeth J. Rushing, Paul M.J. McSheehy, Dirk Weber, Peter R. Allegrini, Dorothea Weniger, Urs M. Lütolf, Alexander Knuth, Yasuhiro Yonekawa, Krisztina Barath, Angela Broggini-Tenzer, Martin Pruschy & Silvia Hofer. (2012) Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial. Oncology 83:1, pages 1-9.
Crossref
Jianping Deng, Guodong Gao, Liang Wang, Tao Wang, Jia Yu & Zhenwei Zhao. (2011) Stratifin expression is a novel prognostic factor in human gliomas. Pathology - Research and Practice 207:11, pages 674-679.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.